Format

Send to

Choose Destination
Hipertens Riesgo Vasc. 2015 Jan-Mar;32(1):21-6. doi: 10.1016/j.hipert.2014.06.001. Epub 2014 Jul 15.

[The association of hyperinsulinemia with cardiovascular risk and cancer poses new challenges in the treatment of the insulin resistance type 2 diabetes patient].

[Article in Spanish]

Author information

1
Unitat d́Endocrinologia, Servei de Medicina Interna, Hospital Universitari de ĹEsperit Sant, Santa Coloma de Gramenet, Barcelona, España. Electronic address: anubiola@hes.scs.es.
2
Unitat d́Endocrinologia, Servei de Medicina Interna, Hospital Universitari de ĹEsperit Sant, Santa Coloma de Gramenet, Barcelona, España.
3
Unitat de Nutrició, PAMEM (IMAS), Barcelona, España.

Abstract

Hyperinsulinemia has been associated with cardiovascular risk, both independently and by facilitating the development of other cardiovascular risk factors. It has also been associated by different routes with increased cancer risk. Thus, this makes it a priority to identify and treat the hyperinsulinemic patient early in order to delay or prevent cardiovascular risk and the development of type 2 diabetes mellitus (T2DM) and certain types of cancer. A new strategy is needed for the treatment of hyperglycemia in these patients, whose primary objective would be to achieve weight loss, reduce insulin resistance and thereby hyperinsulinemia. That is, prescribing insulin secretors and insulin should be used with caution in these patients.

KEYWORDS:

Cancer; Cardiovascular; Cáncer; Diabetes tipo 2; Hiperinsulinemia; Hyperinsulinemia; Insulin resistance; Insulinorresistencia; Type 2 diabetes

PMID:
26179854
DOI:
10.1016/j.hipert.2014.06.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center